Stroke AI: End‑to‑End.
Real-Time Detection. Predictive Intelligence.
Fast, accurate, consistent AI triage for acute stroke response and transfer decisions.
Hyper Insight AI Detection Solutions
Comprehensive Stroke AI Platform
Hyper Insight™ – ICH
FDA K240353AI software that triages suspected brain hemorrhage within seconds on non-contrast CT and alerts clinicians to potential findings.
Source: Clinical Study Report, Protocol No. SKAIICH-02, Hyper Insight-ICH FDA Clinical Performance Evaluation, Midstate Medical Center, USA.
Radiological computer-aided triage and notification software. Hyper Insight™ – ICH functions as a notification and triage tool — supporting, not replacing, medical judgment. Final diagnosis and treatment decisions remain the responsibility of qualified medical professionals.
Medical Insight+™ Brain Hemorrhage
RUOKFDA(ICH, SAH, IPH, SDH, EDH)
Not cleared or approved by the US Food and Drug Administration (FDA). This software is not for clinical use in the United States and is provided for research, evaluation, and educational purposes only. The indication for use in pediatric patients (under 18 years of age) is currently under review by the Ministry of Food and Drug Safety (MFDS) and has not yet received regulatory approval. Clinical use in pediatric populations is subject to the outcome of this review.
AI-Assisted Reader Performance Improvement
Patient-level improvement when radiologists use Medical Insight+™ Brain Hemorrhage vs. unassisted reads.
+3.2% accuracy improvement among non-radiologists — the greatest gain across all reader groups.
ICC improved from Good (0.8475) to Excellent (0.9193). All metrics measured at patient level.
Source: Clinical Study Report, Protocol No. SKAIICH-01, Ver. 2.0, Seoul National University Hospital & Ajou University Hospital, Korea. CRIS: KCT0006734.
Top 15 Industry Features Avail.
Industry-standard integration capabilities available with PurpleAI deployments.
Clinical Evidence
Validated by Rigorous Clinical Research
Multi-Center External Validation
AI Performance in Patient-wise Analysis
AI Sensitivity by AIH Subtype
Multi-Center External Validation
Korean Multi-center, retrospective, crossover study
| Without AI | With AI | P- value | |
|---|---|---|---|
| Sensitivity | 94.4% | 97.2% | 0.0017 |
| Specificity | 95.0% | 96.9% | 0.0376 |
| Accuracy | 94.7% | 97.0% | 0.0075 |
Performance vs. Peers
| Metric | Rank |
|---|---|
| AUC | #1 |
| Specificity | #2 |
| Speed | #2 |
| Sensitivity | #3 |
Who We Serve
Solutions for Every Emergency Room in Rural and Critical Access Hospitals.
Clinicians
- Flags hemorrhage in 16 seconds on average. Non-radiologists reach specialist-level accuracy.
- Non-specialist uplift+3.15% accuracy improvement for non-radiologists.
- Subspecialty gap coverageAI compensates for absent neuroradiology in rural/off-hours settings.
- Worklist prioritizationSuspected ICH cases surfaced first — frees attention for highest-risk patients.
Source: Yun TJ, et al. npj Digital Medicine, Springer Nature (2023). p=0.0072.
Care Teams
- Automated real-time alertsMobile push alerts to your entire care team upon suspected ICH detection.
- Secure DICOM viewerSmart messaging and team invitations for instant case collaboration from anywhere.
- Stroke code accelerationSupports faster door-to-imaging and imaging-to-treatment times.
Hospitals & Administrators
- Up to 70% cost savings compared to peer solution providers.
- Reduced dependence on outsourced readsThe primary cost driver for low-volume sites.
- 12-month zero-cost pilotNo costs for deployment, integration, and licensing. Limited-time offer for US reference building.
- Cloud-nativeFlexible deployment options.
What Clinicians Say
Trusted by Medical Professionals
It will be very helpful for physicians who lack expertise but must make initial judgments in emergency cases.
Successfully detected small findings and correctly identified negatives as negative. The AI software helps clinicians who have difficulty distinguishing beam hardening artifacts.
When detecting small SAH (subarachnoid hemorrhage), the AI assistance helps accurately review many images in a short amount of time.
What impressed me most was the software's ability to distinguish real hemorrhage from look-alikes. Partial volume artifacts — where bone and brain tissue overlap — can easily mimic a small subarachnoid hemorrhage on CT, and normal intracranial calcifications appear hyperdense enough to fool most deep learning algorithms into flagging them as bleeds. These are areas where even experienced neuroradiologists have to slow down and look twice. PurpleAI's system correctly identified both as non-hemorrhage, avoiding false positives that would otherwise erode a clinician's trust in the tool.
The system consistently detected small-volume hemorrhages that are among the hardest findings to catch on non-contrast CT — thin subdural collections along the anterior falx cerebri, trace subarachnoid blood in a single sulcus. These are the cases that get missed on overnight reads or by physicians who don't specialize in neuroimaging. The AI flagged them accurately and localized them with color mapping, giving the reader a clear starting point instead of having to hunt through every slice.
Testimonials from medical end users at Korean academic university hospitals
See It In Action
Product Demo
Patient ID: 12847 · NCCT
Brain aneurysm suspected
No abnormalities detected
Cross-Platform
Optimized for all devices
ICH case needs immediate review
On it. Checking now
I'll join the consultation
Mobile DICOM Viewer
DICOM Access Anytime, Anywhere
Your stroke care team stays connected with real-time mobile notifications and a full-featured DICOM viewer.
Instant Specialist Notification
Auto Alerts for Suspected ICH
Seamless Team Collaboration
Smart Messaging and Invitations for Instant Case Review
Mobile DICOM Viewing
Full Diagnostic-Quality Images Review
Predictive Intelligence
StrokeShieldAI™
"Advance from rapid stroke detection toward predictive intelligence that anticipates patient trajectories through multimodal data, transforming acute stroke care from reactive response to proactive decision-making."
StrokeShieldAI ArchitectureImaging Data, EHR, Vital Signs flowing into AI Engine producing Result Report and Alert System
Trusted By Leading Institutions
Our Partners
Strategic partners expanding our reach and capabilities
Joshua N. Goldstein, MD, PhD
Professor, Harvard Medical School · Vice Chair for Faculty Affairs, Dept. of Emergency Medicine, Mass General Brigham · Director, Center for Neurologic Emergencies, MGH. Research focus: hematoma expansion, risk models, early neurological deterioration.
Get In Touch
Contact Us
We'd love to hear from you
Headquarters
3rd Floor, 18 Teheran-ro 20-gil
Gangnam-gu, Seoul, Korea 06235
purpleai@purple-ai.co
Phone
+82 10-2923-4270
Website
purple-ai.co
Distribution Partners (US)
SaveLife.AI · CARPL.ai · VSee
Request a Demo
Terms of Use
1. Acceptance of Terms
By accessing or using the PurpleAI website and services ("Services"), you agree to be bound by these Terms of Use. If you do not agree to these terms, do not use the Services.
2. Description of Services
PurpleAI provides AI-powered medical imaging analysis software, including Hyper Insight™ and Medical Insight+™ products. These products are intended for use by licensed healthcare professionals and institutions. All products are subject to their respective regulatory clearances and intended use statements.
3. Medical Disclaimer
PurpleAI products are designed to assist — not replace — the clinical judgment of qualified healthcare professionals. AI-generated outputs are advisory in nature and must be reviewed by a licensed clinician before any clinical action is taken. PurpleAI is not responsible for clinical decisions made based on AI outputs.
4. Regulatory Status
Hyper Insight™ – ICH is FDA 510(k) cleared (K240353) for clinical use in the United States. Medical Insight+™ products are KFDA-approved and available for Research Use Only (RUO) in the US market. Products labeled "Pipeline" or "In Development" are not cleared for clinical use in any market.
5. Intellectual Property
All PurpleAI products, documentation, algorithms, and trademarks (including Hyper Insight™, Medical Insight+™, and StrokeShieldAI™) are the exclusive property of Purple AI Inc. Unauthorized reproduction, distribution, or reverse engineering is strictly prohibited.
6. Limitation of Liability
To the maximum extent permitted by applicable law, PurpleAI shall not be liable for any indirect, incidental, special, consequential, or punitive damages arising from your use of the Services.
Privacy Policy
1. Information We Collect
We collect information you provide directly (name, email, organization, role) when requesting a demo or contacting us. We also collect standard usage data (IP address, browser type, pages visited) through analytics tools.
2. Protected Health Information (PHI)
PurpleAI processes medical imaging data exclusively within HIPAA-compliant, ISO 27001-certified infrastructure. All PHI is encrypted in transit and at rest. We do not sell, share, or use PHI for marketing purposes. BAA agreements are available for all US healthcare customers.
3. Data Retention
Contact form data is retained for business relationship management. Medical imaging data retention follows customer-specific BAA terms and applicable regulations (HIPAA, GDPR where applicable).
4. Third-Party Services
We use cloud infrastructure providers (subject to our security requirements) for hosting and processing. Distribution partners (SaveLife.AI, CARPL.ai, VSee) may process data under their own privacy policies when accessed through their platforms.
5. Your Rights
You may request access to, correction of, or deletion of your personal data by contacting purpleai@purple-ai.co. We respond to all data requests within 30 days.
Security Policy
1. Certifications & Compliance
PurpleAI maintains the following active certifications:
- ISO 27001 — Information Security Management System
- ISO 13485 — Medical Device Quality Management System
- GMP — Good Manufacturing Practice
- FDA 510(k) — US Federal regulatory clearance (K240353)
- Korea MFDS — Korean regulatory approval
2. Data Encryption
All data is encrypted using AES-256 at rest and TLS 1.3 in transit. DICOM images are processed within isolated, encrypted compute environments with no persistent storage beyond the analysis session unless explicitly configured by the customer.
3. Cloud Infrastructure
PurpleAI uses cloud-native deployment with no on-premise hardware required. Infrastructure is hosted in SOC 2-compliant data centers with 99.9% uptime SLA. Multi-region deployment available for enterprise customers.
4. Access Control
Role-based access control (RBAC), multi-factor authentication (MFA), and audit logging are standard across all deployments. Integration with hospital SSO/LDAP systems is supported.
5. Vulnerability Management
We conduct regular penetration testing, dependency scanning, and security audits. Responsible disclosure inquiries can be directed to purpleai@purple-ai.co.
Ready to Transform Your Stroke Workflow?
Join 40+ hospitals already using PurpleAI. Flexible deployment for institutions of all sizes.